# OnCo record anti-vegf-drugs-around-surgery (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/anti-vegf-drugs-around-surgery/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "anti-vegf-drugs-around-surgery" ;
  schema:name "Bevacizumab and other anti-VEGF drugs around surgery: pausing before and restarting after"@en ;
  schema:alternateName "holding bevacizumab before surgery"@en, "anti-angiogenic drugs and wound healing"@en, "VEGF inhibitor surgery interval"@en, "stopping TKI before surgery"@en, "Avastin before surgery"@en ;
  schema:description "Drugs that block blood vessel growth, such as bevacizumab (Avastin), ramucirumab, aflibercept and tablets like cabozantinib, lenvatinib or sunitinib, slow the healing of wounds. Before planned surgery they are paused, for between 2 days and 4 weeks depending on the drug, and restarted only once the wound has healed, usually at least 2 to 4 weeks after a big operation."@en ;
  schema:url <https://onco.cc/protocols/anti-vegf-drugs-around-surgery/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:related <https://onco.cc/protocols/surgical-site-infection-prevention/>, <https://onco.cc/protocols/routine-preoperative-tests/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/ziv-aflibercept/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/tivozanib/> ;
  onco:terms <https://onco.cc/terms/antiangiogenic-toxicities/> .